381 related articles for article (PubMed ID: 23624870)
1. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
4. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
5. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
8. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Buchholz S; Schally AV; Engel JB; Hohla F; Heinrich E; Koester F; Varga JL; Halmos G
Proc Natl Acad Sci U S A; 2007 Feb; 104(6):1943-6. PubMed ID: 17261802
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
Guo J; Schally AV; Zarandi M; Varga J; Leung PC
Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
[TBL] [Abstract][Full Text] [Related]
11. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
12. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
[TBL] [Abstract][Full Text] [Related]
13. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
14. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
[TBL] [Abstract][Full Text] [Related]
16. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
17. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
[TBL] [Abstract][Full Text] [Related]
19. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
[TBL] [Abstract][Full Text] [Related]
20. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
